Announcements Trials
Browse Landscape

Phase

Phase 1 9Phase 1/2 6Phase 2 2Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Renal Cell 3Melanoma 2Kidney Neoplasms 2Solid Tumors 1Solid Tumor 1Skin Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Radiosurgery 6pembrolizumab 4Carboplatin 3atezolizumab 2aldesleukin 2Paclitaxel 2Nivolumab 2Cyclophosphamide 2osimertinib 1durvalumab 1avelumab 1amatuximab 1Vitamin A 1Tobacco Use Cessation Devices 1Thoracic Surgical Procedures 1Taxes 1Radiotherapy 1Radiation Dose Hypofractionation 1RXDX-106 1Proton Therapy 1Pemetrexed 1Optical Fibers 1Oncolytic Virotherapy 1Itraconazole 1Interleukin-2 1Fluorodeoxyglucose F18 1Ethiodized Oil 1Erlotinib Hydrochloride 1Docetaxel 1Dihematoporphyrin Ether 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Carcinoma, Non-Small-Cell Lung × Interleukin-2 × Clear all
NCT03224871 2020-04-07

UCDCC#269: A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC.

University of California, Davis

Phase EARLY_PHASE1 Completed
3 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡